Printed on recycled paper131st MAINE LEGISLATURE
FIRST REGULAR SESSION-2023
Legislative Document No. 132
S.P. 71 In Senate, January 10, 2023
An Act to Require Health Insurance Carriers to Provide Coverage 
for Blood Testing for Perfluoroalkyl and Polyfluoroalkyl Substances
Reference to the Committee on Health Coverage, Insurance and Financial Services 
suggested and ordered printed.
DAREK M. GRANT
Secretary of the Senate
Presented by Senator BRENNER of Cumberland.

Page 1 - 131LR0143(01)1Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  24-A MRSA ยง4320-V is enacted to read:
3ยง4320-V.  Coverage for blood testing for perfluoroalkyl and polyfluoroalkyl 
4substances
51.  Definition.  As used in this section, unless the context otherwise indicates, 
6 "perfluoroalkyl and polyfluoroalkyl substances" means any member of the class of 
7 fluorinated organic chemicals containing at least one fully fluorinated carbon atom.
82.  Required coverage.  A carrier offering a health plan in this State shall provide 
9 coverage for blood testing for perfluoroalkyl and polyfluoroalkyl substances to an enrollee.
10Sec. 2.  Application.  This Act applies to all policies, contracts and certificates 
11 executed, delivered, issued for delivery, continued or renewed in this State on or after 
12 January 1, 2024.  For purposes of this Act, all contracts are deemed to be renewed no later 
13 than the next yearly anniversary of the contract date.
14SUMMARY
15 This bill requires carriers offering health plans in this State to provide coverage for 
16 blood testing for perfluoroalkyl and polyfluoroalkyl substances.  The requirements of the 
17 bill apply to health plans issued or renewed on or after January 1, 2024.15
16
17
